1. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. (October 2017) Authors: Alù, M.; Ancona, C.; Andreis, D.; Bajardi, E.; Benedetto, C.; Berardi, R.; Bordin, E.; Butti, C.; Capri, G.; Cicchiello, F.; Cocciolone, V.; Dester, M.; D'Onofrio, L.; Febbraro, A.; Ferrarini, I.; Fotia, V.; Gervasi, E.; Guaitoli, G.; Licata, L.; Liscia, N. Journal: Breast Issue: Volume 35(2017) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗